Compare Kinder Morgan Inc (KMI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs ResMed Inc. — how do they compare? Kinder Morgan Inc trades at $31.74 (market cap $70.10B), while ResMed Inc. trades at $225.19 (market cap $32.61B). The key difference: Kinder Morgan Inc is far larger — about 2.1× ResMed Inc.'s market cap, and Kinder Morgan Inc pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| KMI | RMD | |
|---|---|---|
Market Cap | $70.10B | $32.61B |
Sector | Energy | Health |
52-Week High | $34.31 | $293.73 |
52-Week Low | $25.84 | $182.82 |
Enterprise Value | $102.15B | $31.97B |
Dividend Yield | 3.75% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KMI trades at $31.70, up 0.99% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates, and raised full-year guidance. Recent news highlights a $5 billion joint venture for the Western Gateway Pipeline, signaling growth in natural gas infrastructure. Fundamentals show solid revenue growth, with 2025 revenue at $16.94 billion and net income margin improving to 19.31%.
The outlook is positive due to contracted cash flows and a robust project pipeline, but risks include high debt levels and exposure to energy market volatility. Analyst sentiment is mixed, with a near-even split between buy and hold ratings. The stock offers a dividend yield supported by stable cash generation, though valuation multiples like a P/E of 20.31 may limit near-term upside.
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
